Analysts think ETNB stock price could increase by 282%
Dec 27, 2024, 12:26 PM
-10.99%
What does ETNB do
89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
9 analysts think ETNB stock price will increase by 282.02%. The current median analyst target is $30.60 compared to a current stock price of $8.01. The lowest analysts target is $12.12 and the highest analyst target is $51.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
